Adaptive Biotechnologies (ADPT) Accumulated Expenses (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Accumulated Expenses data on file, last reported at $7.5 million in Q1 2026.

• Quarterly Accumulated Expenses rose 16.42% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (up 16.42% YoY) and the FY2025 annual result came in at $17.0 million, up 8311.88% from the prior year.
• Accumulated Expenses slipped to $7.5 million in Q1 2026 per ADPT's latest filing, from $17.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $17.0 million in Q4 2025, with the low at $154000.0 in Q4 2023.
• Average Accumulated Expenses over 5 years is $7.6 million, with a median of $6.7 million recorded in 2024.
• Year-over-year, Accumulated Expenses plunged 97.51% in 2022 and surged 8311.88% in 2025.
• Adaptive Biotechnologies' Accumulated Expenses stood at $233000.0 in 2022, then sank by 33.91% to $154000.0 in 2023, then jumped by 31.17% to $202000.0 in 2024, then surged by 8311.88% to $17.0 million in 2025, then sank by 56.07% to $7.5 million in 2026.
• Business Quant data shows ADPT's Accumulated Expenses at $7.5 million in Q1 2026, $17.0 million in Q4 2025, and $12.7 million in Q3 2025.